We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Zinc Isotope Test Helps Detect Early Breast Cancer

By LabMedica International staff writers
Posted on 23 Dec 2014
Print article
Image: The Nu Plasma II multiple collector inductively coupled plasma mass spectrometry instrument (MC-ICP-MS) (Photo courtesy of Nu Instruments).
Image: The Nu Plasma II multiple collector inductively coupled plasma mass spectrometry instrument (MC-ICP-MS) (Photo courtesy of Nu Instruments).
It may be possible to detect the early signs of breast cancer with a test that measures changes in zinc isotopes as measurable changes in zinc isotope composition can be detected in breast tissue and could be used as a biomarker for early breast cancer.

Breast cancers that are found after they start to cause symptoms, for example, a new lump or swelling, or changes in nipple shape and texture, are usually larger and more likely to have started spreading than breast cancers found before symptoms emerge. The size of a breast tumor and how far it has spread are two of the most important factors in predicting the success of treatment and the longer-term outlook for the patient.

Scientists at the University of Oxford (UK) determined the zinc concentrations and isotopic composition of blood and blood serum of healthy controls and breast cancer patients, alongside a suite of 10 breast tissues, predominantly obtained from breast cancer patients. They applied techniques normally used by earth scientists to understand climate change and the birth of planets, to study how the body processes metals.

The techniques which are over 100 times more sensitive to changes in metal composition than any clinical laboratory instruments, measure the levels of trace metals in terms of the relative proportions of their different isotopic forms.

Zinc and copper concentrations were determined by multiple collector inductively coupled plasma mass spectrometry (MC-ICP-MS) and inductively coupled plasma atomic emission spectroscopy (ICP-AES). Isotope analyses were performed using the Nu Instruments Nu Plasma HR MC-ICP-MS at the appropriate resolution mode (Copper: low, Zinc: medium) with either an Aridus (Cetac; Omaha, NE, USA) or a desolvating sample system (DSN) (Nu Instruments, Oxford, UK). The reproducibility of the methods was monitored by repeat measurements of an in house standard alongside sample.

The investigators found that the breast cancer tumors had a significantly lighter zinc isotopic composition than the blood, serum and healthy breast tissue of both the breast cancer patients and the healthy controls. The team suggests the subtle differences in zinc composition occur because tumor cells process the metal differently to normal cells. They also found similar changes in copper in one of the breast cancer patients.

Fiona Larner, PhD, the lead author of the study, said, “We have known for over 10 years that breast cancer tissue carries high levels of zinc, but the underlying processes that cause this are not well understood. Our study shows that techniques commonly used in earth sciences can help us to understand not only how zinc is used by tumor cells but also how breast cancer can lead to changes in zinc in an individual's blood. Further research is already under way to see what changes in other metals may be caused by other cancers.” The study was published on December 1, 2014, in the journal Metallomics.

Related Links:

University of Oxford 
Cetac 
Nu Instruments  


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.